← 產業報告目錄

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-05-09頁數 967報告編號 MD3680

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The injectable drug delivery devices market is projected to reach USD 373.7 billion by 2030 from USD 256.3 billion in 2025, at a CAGR of 7.8% during the forecast period. The injectable drug delivery formulations market is projected to reach USD 661.1 billion by 2030 from USD 434.0 billion in 2025, at a CAGR of 8.8% during the forecast period. The injectable drug delivery market is experiencing rapid transformation due to the increasing demand for patient-centric, targeted, and minimally invasive treatment solutions. A significant trend in this market is the shift toward self-injection technologies, which include autoinjectors, pen injectors, and wearable injectors. These advancements enhance patient compliance and facilitate at-home care, which is especially important for managing chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis. Technological advancements are increasingly shaping the market. Smart injectors equipped with connectivity features, dose tracking, and reminder systems are becoming more popular, reflecting the broader trend toward digital healthcare. Furthermore, the integration of microneedles and needle-free injectors is helping to reduce the pain and anxiety often associated with traditional syringes, particularly for pediatric and geriatric populations. The pharmaceutical industry increasingly focuses on long-acting formulations, biologics, and biosimilars, requiring precise delivery systems. This trend is fostering closer collaboration between drug developers and device manufacturers. Additionally, regulatory bodies are updating their frameworks to better support combination products, which is helping to accelerate product approvals. "By device, the self-injection devices segment is projected to grow at the highest CAGR during the forecast period." From 2025 to 2030, the self-injection devices segment is expected to grow at the highest rate within the injectable drug delivery market. This growth is driven by a global shift toward decentralized care, an increase in the prevalence of chronic diseases, and a growing emphasis on patient autonomy. Self-injection devices, which include autoinjectors, pen injectors, and wearable injectors, provide convenience and precision while reducing the need for clinical settings. This makes them particularly suitable for long-term therapies. In the US and Canada, growth is driven by a high adoption rate of biologics for treating autoimmune and metabolic disorders, along with favorable reimbursement policies and the integration of digital technology in healthcare. Demand has increased significantly in Europe, particularly Germany, France, and the UK, due to the expanding geriatric population and well-structured chronic disease management programs. In the Asia Pacific region, countries such as Japan, China, and India are experiencing rapid growth due to improved healthcare access, increased patient awareness, and a rise in the availability of biosimilars. Technological trends such as smart connectivity features, dose memory, and pain-reduction technologies make devices more appealing. The COVID-19 pandemic has also accelerated the adoption of self-care, as patients tend to avoid hospitals and prefer administering treatments at home. Collaborations between pharmaceutical companies and device manufacturers are increasing, allowing for customized solutions for injectable therapies. Overall, the rapid growth of this segment reflects a strong combination of clinical needs, patient preferences, and technological advancements. "By formulation packaging, the ampoules segment accounted for the largest market share in 2024." The ampoules segment was the leading contributor to market share within the injectable drug delivery market in 2024. Ampoules are the fastest-growing packaging segment in this market, driven by their superior sterility, affordability, and adaptability to a wide range of drug formulations. Typically made of glass or plastic, ampoules are ideal for preserving single-dose injectable solutions without the risk of contamination, making them highly preferred in acute care and hospital settings. In developing economies like India, Brazil, and Vietnam, the cost-effectiveness of ampoules encourages their widespread use in government vaccination and immunization programs. Additionally, their compatibility with various biologics and small-molecule drugs further facilitates adoption across therapeutic areas such as oncology, anti-infectives, and hormonal therapies. “The Asia Pacific (APAC) region is expected to witness the highest growth rate during the forecast period.” The Asia Pacific region is becoming the fastest-growing area in the injectable drug delivery market, driven by a combination of demographic, economic, and healthcare factors. The increasing prevalence of chronic diseases, particularly diabetes and cancer, in large countries like China and India, is creating a greater demand for advanced injectable therapies. Additionally, as access to biologics expands, there is an increased need for user-friendly devices, such as autoinjectors and pen injectors. In China, supportive government policies, increasing investment in research and development, and a thriving biotechnology sector are driving the adoption of innovative drug delivery systems. Meanwhile, India, benefiting from a growing generics market, is also seeing significant growth in self-injection devices and biosimilars. Additionally, Southeast Asian countries like Vietnam and Thailand are enhancing their healthcare infrastructure and improving access to specialty care, which is boosting regional demand. Urbanization, increasing disposable incomes, and a growing aging population contribute to the trend as patients and providers seek convenient, home-based treatment options. Additionally, regional manufacturing capabilities and cost-effective production attract partnerships from global pharmaceutical and device firms. Breakdown of supply-side primary interviews: • By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%) • By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%) • By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%) Breakdown of demand-side primary interviews: • By Company Type: Hospitals (60%), Ambulatory Surgical Centers (25%), and Home Care Settings (15%) • By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%) • By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%) Research Coverage This report studies the injectable drug delivery market based on product, therapeutic application, formulation, packaging, usage pattern, site of administration, end user, and region. The report also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six main regions and respective countries. Reasons to Buy the Report The report can assist both established companies and new or smaller firms understand the market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below. This report provides insights into the following points: • Analysis of key drivers (increasing chronic diseases, increasing biologics, and technological advancements), restraints (infections associated with needle-stick injuries), challenges (other methods of injectable drug delivery available in the market), and opportunities (increasing demand for generic medicines and biosimilars) influencing the growth of injectable drug delivery market. • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the injectable drug delivery market. • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of injectable drug delivery procedures across regions. • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the injectable drug delivery market. • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the injectable drug delivery market.
目錄 Table of Contents
1 INTRODUCTION 72 1.1 STUDY OBJECTIVES 72 1.2 MARKET DEFINITION 72 1.3 MARKET SCOPE 73 1.3.1 MARKETS SEGMENTATION 73 1.3.2 REGIONAL SEGMENTATION 74 1.3.3 YEARS CONSIDERED 74 1.3.4 INCLUSIONS AND EXCLUSIONS 75 1.4 CURRENCY CONSIDERED 75 1.5 STAKEHOLDERS 76 1.6 SUMMARY OF CHANGES 76 2 RESEARCH METHODOLOGY 78 2.1 RESEARCH DATA 78 2.1.1 SECONDARY DATA 79 2.1.1.1 Key secondary sources 80 2.1.2 PRIMARY DATA 80 2.1.2.1 Primary sources 81 2.1.2.2 Key data from primary sources 82 2.1.2.3 Breakdown of primaries 83 2.2 MARKET SIZE ESTIMATION 84 2.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH 85 2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 86 2.2.3 APPROACH 3: TOP-DOWN APPROACH 87 2.2.4 APPROACH 4: BOTTOM-UP APPROACH 87 2.2.5 APPROACH 4: PRIMARY INTERVIEWS 88 2.2.6 APPROACH 5: DEMAND-SIDE APPROACH 88 2.2.7 APPROACH 6: VOLUME DATA ANALYSIS 88 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 90 2.4 MARKET SHARE ASSESSMENT 90 2.5 RESEARCH ASSUMPTIONS 91 2.5.1 STUDY ASSUMPTIONS 91 2.5.2 GROWTH RATE ASSUMPTIONS 91 2.6 RESEARCH LIMITATIONS 91 2.7 RISK ASSESSMENT 92 3 EXECUTIVE SUMMARY 93   4 PREMIUM INSIGHTS 99 4.1 INJECTABLE DRUG DELIVERY MARKET OVERVIEW 99 4.2 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET OVERVIEW 100 4.3 INJECTABLE DRUG DELIVERY MARKET: REGIONAL MIX 100 4.4 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 101 4.5 INJECTABLE DRUG DELIVERY MARKET: DEVELOPING VS. DEVELOPED MARKETS 101 5 MARKET OVERVIEW 102 5.1 MARKET DYNAMICS 102 5.1.1 DRIVERS 103 5.1.1.1 Growing demand for self-injection devices 103 5.1.1.2 Advancements in drug delivery technologies 103 5.1.1.3 Rising prevalence of chronic diseases 105 5.1.1.4 Growing adoption of biologics and biosimilars 106 5.1.2 RESTRAINTS 107 5.1.2.1 Infections associated with needlestick injuries 107 5.1.2.2 Stringent government regulations 107 5.1.3 OPPORTUNITIES 108 5.1.3.1 Development of novel drug delivery systems 108 5.1.3.2 Growing preference for home-based care devices 108 5.1.3.3 Growth opportunities in emerging economies 109 5.1.4 CHALLENGES 109 5.1.4.1 Alternative methods of drug delivery 109 5.1.4.2 Complexities in developing wearable drug delivery systems 110 5.2 INDUSTRY TRENDS 110 5.2.1 REUSABLE DRUG DELIVERY DEVICES 110 5.2.2 PREFILLED BIOLOGICS 110 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 111 5.4 PRICING ANALYSIS 112 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 112 5.4.1.1 Average selling price trend of key players, by device type 112 5.4.1.2 Average selling price trend of key players, by pen injectors 112 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 113 5.4.2.1 Average selling price trend of pen injectors, by region 113 5.4.2.2 Average selling price trend of needle-free injectors, by region 114 5.4.2.3 Average selling price trend of autoinjectors, by region 114 5.4.2.4 Average selling price trend of wearable injectors, by region 115 5.5 VALUE CHAIN ANALYSIS 115 5.5.1 RESEARCH & PRODUCT DEVELOPMENT 116 5.5.2 RAW MATERIAL PROCUREMENT 116 5.5.3 MANUFACTURING 116 5.5.4 MARKETING, SALES & DISTRIBUTION, AND AFTER-SALES SERVICES 116 5.6 SUPPLY CHAIN ANALYSIS 116 5.7 ECOSYSTEM ANALYSIS 117 5.8 INVESTMENT AND FUNDING SCENARIO 120 5.9 TECHNOLOGY ANALYSIS 120 5.9.1 KEY TECHNOLOGIES 120 5.9.1.1 Autoinjectors and smart injection devices 120 5.9.1.2 Needle-free injection systems and microneedle patches 121 5.9.1.3 Wearable injectors for high-volume delivery 121 5.9.2 COMPLEMENTARY TECHNOLOGIES 122 5.9.2.1 Nanotechnology 122 5.9.2.2 Biodegradable polymers 122 5.9.3 ADJACENT TECHNOLOGIES 123 5.9.3.1 Artificial intelligence and digital therapeutics 123 5.9.3.2 Alternative routes of administration 123 5.10 PATENT ANALYSIS 124 5.10.1 PATENT PUBLICATION TRENDS FOR INJECTABLE DRUG DELIVERY 124 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS 125 5.11 TRADE ANALYSIS 126 5.11.1 TRADE DATA FOR HS CODE 901890 127 5.11.1.1 Import data 127 5.11.1.2 Export data 127 5.11.2 TRADE DATA FOR HS CODE 90183100 128 5.11.2.1 Import data 128 5.11.2.2 Export data 128 5.12 KEY CONFERENCES AND EVENTS, 2025–2026 129 5.13 CASE STUDY ANALYSIS 130 5.14 REGULATORY LANDSCAPE 132 5.14.1 REGULATORY ANALYSIS 132 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 133 5.15 PORTER’S FIVE FORCES ANALYSIS 136 5.15.1 BARGAINING POWER OF SUPPLIERS 136 5.15.2 BARGAINING POWER OF BUYERS 137 5.15.3 THREAT OF NEW ENTRANTS 137 5.15.4 THREAT OF SUBSTITUTES 137 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 137 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 138 5.16.1 KEY STAKEHOLDERS 138 5.16.2 BUYING CRITERIA 138 5.16.2.1 Buying criteria for injectable drug delivery devices 138 5.16.2.2 Buying criteria for injectable drug delivery devices with formulations 139   5.17 PIPELINE ANALYSIS 140 5.18 REIMBURSEMENT ANALYSIS 149 5.19 UNMET NEEDS/END-USER EXPECTATIONS 149 5.20 IMPACT OF AI/GEN AI IN INJECTABLE DRUG DELIVERY MARKET 150 5.20.1 INTRODUCTION 150 5.20.2 MARKET POTENTIAL OF AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM 150 5.20.3 AI USE CASES 151 5.20.4 KEY COMPANIES IMPLEMENTING AI IN INJECTABLE DRUG DELIVERY DEVICES 152 5.20.5 FUTURE OF GEN AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM 152 5.21 IMPACT OF 2025 US TARIFF 153 5.21.1 INTRODUCTION 153 5.21.2 KEY TARIFF RATES 154 5.21.3 PRICE IMPACT ANALYSIS 155 5.21.4 IMPACT ON COUNTRY/REGION 155 5.21.4.1 North America 155 5.21.4.2 Asia Pacific 156 5.21.4.3 Europe 157 5.21.4.4 Latin America 157 5.21.5 IMPACT ON END-USE INDUSTRIES 158 6 INJECTABLE DRUG DELIVERY, BY PRODUCT 159 6.1 INTRODUCTION 160 6.2 DEVICES 162 6.2.1 CONVENTIONAL INJECTION DEVICES 166 6.2.1.1 By material 171 6.2.1.1.1 Glass injectable devices 171 6.2.1.1.1.1 Light protection, temperature resistance, and impermeability properties to drive market 171 6.2.1.1.2 Plastic injectable devices 174 6.2.1.1.2.1 Rapid increase in demand for syringes to aid growth 174 6.2.1.2 By product 176 6.2.1.2.1 Fillable syringes 176 6.2.1.2.1.1 Ease of use and variable dosing formulations to boost market 176 6.2.1.2.2 Prefilled syringes 178 6.2.1.2.2.1 Minimal drug waste and low weight & space requirements to propel market 178 6.2.1.3 By usability 180 6.2.1.3.1 Reusable injection devices 180 6.2.1.3.1.1 Cost-effective nature to contribute to growth 180 6.2.1.3.2 Disposable injection devices 182 6.2.1.3.2.1 Growing preference for ready-to-use devices to drive market 182   6.2.2 SELF-INJECTION DEVICES 184 6.2.2.1 Needle-free injectors 188 6.2.2.1.1 By product 191 6.2.2.1.1.1 Fillable needle-free injectors 191 6.2.2.1.1.2 Prefilled needle-free injectors 193 6.2.2.1.2 By technology 195 6.2.2.1.2.1 Jet-based needle-free injectors 195 6.2.2.1.2.2 Spring-based needle-free injectors 197 6.2.2.1.2.3 Laser-powered needle-free injectors 199 6.2.2.1.2.4 Vibration-based needle-free injectors 201 6.2.2.1.3 By usability 202 6.2.2.1.3.1 Reusable needle-free injectors 202 6.2.2.1.3.2 Disposable needle-free injectors 204 6.2.2.2 Autoinjectors 206 6.2.2.2.1 By product 209 6.2.2.2.1.1 Fillable autoinjectors 209 6.2.2.2.1.2 Prefilled autoinjectors 211 6.2.2.2.2 By technology 213 6.2.2.2.2.1 Automated autoinjectors 213 6.2.2.2.2.2 Manual autoinjectors 215 6.2.2.2.3 By design 217 6.2.2.2.3.1 Standardized autoinjectors 217 6.2.2.2.3.2 Customized autoinjectors 219 6.2.2.2.4 By usability 221 6.2.2.2.4.1 Reusable autoinjectors 221 6.2.2.2.4.2 Disposable autoinjectors 223 6.2.2.3 Pen injectors 225 6.2.2.3.1 By product 228 6.2.2.3.1.1 Single-chambered pen injectors 228 6.2.2.3.1.2 Double-chambered pen injectors. 230 6.2.2.3.2 By design 232 6.2.2.3.2.1 Standard pen injectors 232 6.2.2.3.2.2 Customized pen injectors 234 6.2.2.3.3 By usability 236 6.2.2.3.3.1 Reusable pen injectors 236 6.2.2.3.3.2 Disposable pen injectors 238 6.2.2.4 Wearable injectors 240 6.2.2.4.1 Increasing need for safe and convenient injections to accelerate growth 240 6.2.2.5 Other self-injection devices 243   6.3 FORMULATIONS 245 6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS 248 6.3.1.1 Solutions 251 6.3.1.1.1 High stability and sterility benefits to intensify growth 251 6.3.1.2 Reconstituted/lyophilized formulations 254 6.3.1.2.1 Higher suitability for parenteral administration to aid growth 254 6.3.1.3 Suspensions 256 6.3.1.3.1 Innovations in injectable suspensions for stable and sustained delivery to aid growth 256 6.3.1.4 Emulsions 258 6.3.1.4.1 Advancements in injectable emulsions for controlled and sustained drug delivery to drive market 258 6.3.2 NOVEL DRUG DELIVERY FORMULATIONS 260 6.3.2.1 Colloidal dispersions 263 6.3.2.1.1 Niosomes 265 6.3.2.1.1.1 Low toxicity and economical features to speed up growth. 265 6.3.2.1.2 Liposomes 267 6.3.2.1.2.1 Flexible, biocompatible, and fully biodegradable properties to boost market 267 6.3.2.1.3 Polymeric/mixed micelles 269 6.3.2.1.3.1 Ability to deliver hydrophobic drugs with slower dissolution rates to boost market 269 6.3.2.1.4 Nanoparticles 271 6.3.2.1.4.1 Solid-lipid nanoparticles 273 6.3.2.1.4.2 Nanosuspensions 275 6.3.2.1.4.3 Nanoemulsions 277 6.3.2.2 Microparticles 279 6.3.2.2.1 Microspheres 281 6.3.2.2.1.1 Growing focus of major pharmaceutical companies on microsphere drug delivery to drive market 281 6.3.2.2.2 Microcapsules 283 6.3.2.2.2.1 Higher biocompatibility properties to augment growth 283 6.3.3 LONG-ACTING INJECTABLE FORMULATIONS 285 6.3.3.1 Decreased side effects and overall medical cost reduction to advance growth 285 7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING 287 7.1 INTRODUCTION 288 7.2 AMPOULES 288 7.2.1 EASE OF TRANSPORTATION AND LOW MANUFACTURING COST TO AID GROWTH 288 7.3 VIALS 290 7.3.1 NEED FOR SECURE, DEPENDABLE, AND COST-EFFECTIVE CONTAINERS TO ENCOURAGE GROWTH 290 7.4 CARTRIDGES 292 7.4.1 INCREASING FOCUS ON DOSE ACCURACY AND PATIENT CONVENIENCE TO FACILITATE GROWTH 292 7.5 BOTTLES 294 7.5.1 RISING FOCUS ON SAFE STORAGE OF SOLUTIONS AND EMULSIONS TO FOSTER GROWTH 294 8 INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION 296 8.1 INTRODUCTION 297 8.2 AUTOIMMUNE DISEASES 297 8.2.1 RHEUMATOID ARTHRITIS 301 8.2.1.1 Increased focus on early-stage diagnosis and treatment to amplify growth 301 8.2.2 MULTIPLE SCLEROSIS 303 8.2.2.1 Increasing target patient pool to contribute to growth 303 8.2.3 CROHN’S DISEASE 305 8.2.3.1 Rising use of liposomes to aid growth 305 8.2.4 PSORIASIS 307 8.2.4.1 Lifestyle changes and high disease prevalence to support growth 307 8.2.5 OTHER AUTOIMMUNE DISEASES 309 8.3 HORMONAL DISORDERS 311 8.3.1 DIABETES 314 8.3.1.1 Growing preference for self-injection devices over traditional syringes to drive market 314 8.3.2 REPRODUCTIVE HEALTH DISEASES 316 8.3.2.1 Lack of healthcare facilities and hygiene practices to aid growth 316 8.3.3 ANTITHROMBOTIC/THROMBOLYTIC THERAPY 318 8.3.3.1 High efficacy and safety of heparin for antithrombotic therapy to aid growth 318 8.3.4 OSTEOPOROSIS 320 8.3.4.1 Increasing number of women with calcium and vitamin D deficiencies to foster growth 320 8.3.5 GROWTH HORMONE DEFICIENCY 322 8.3.5.1 Increased need for daily injections of recombinant human growth hormones to fuel market 322 8.4 OBESITY 324 8.4.1 CHANGING SEDENTARY LIFESTYLE AND CONSUMPTION OF OVER-PROCESSED FOODS TO AID GROWTH 324 8.5 CANCER 326 8.5.1 INCREASING LAUNCHES OF NEW VACCINES AND TARGETED THERAPIES TO BOLSTER GROWTH 326 8.6 INFECTIOUS DISEASES 329 8.6.1 GROWING ADVANCEMENTS IN INJECTABLE THERAPIES TO DRIVE MARKET 329 8.7 ORPHAN DISEASES 331 8.7.1 FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT GROWTH 331 8.8 OTHER THERAPEUTIC APPLICATIONS 333 8.8.1 PAIN MANAGEMENT 334 8.8.1.1 Growing focus on treating chronic pain to drive market 334 8.8.2 ALLERGIES 337 8.8.2.1 Increasing prevalence of asthma and eczema to promote growth 337 8.8.3 AESTHETIC TREATMENTS 339 8.8.3.1 Growing popularity of aesthetic procedures to propel market 339 8.8.4 HEPATITIS C 341 8.8.4.1 Need to curb virus spread due to needle reshare to sustain growth 341 8.8.5 HEMOPHILIA 343 8.8.5.1 Increasing need for preventive treatment plans to assist growth 343 9 INJECTABLE DRUG DELIVERY, BY USAGE PATTERN 345 9.1 INTRODUCTION 346 9.2 CURATIVE CARE 346 9.2.1 RISE IN INFECTIOUS DISEASES TO ACCELERATE GROWTH 346 9.3 IMMUNIZATION 348 9.3.1 GROWING DEMAND FOR VACCINES FROM HEALTHCARE ORGANIZATIONS TO DRIVE MARKET 348 9.4 OTHER USAGE PATTERNS 350 10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION 352 10.1 INTRODUCTION 353 10.2 DERMAL-BASED ADMINISTRATION 353 10.2.1 RAPID AND EFFECTIVE METHOD WITH LOW PAIN TO AMPLIFY GROWTH 353 10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION 356 10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT GROWTH 356 10.4 ORGAN-BASED ADMINISTRATION 359 10.4.1 GROWING UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST MARKET 359 10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION 361 10.5.1 INCREASING FOCUS ON PAIN MANAGEMENT TO PROMOTE GROWTH 361 11 INJECTABLE DRUG DELIVERY MARKET, BY END USER 363 11.1 INTRODUCTION 364 11.2 HOSPITALS & CLINICS 364 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH 364 11.3 HOME CARE SETTINGS 366 11.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET 366 11.4 LONG-TERM CARE SETTINGS 368 11.4.1 BOOMING ELDERLY POPULATION AND BURDEN OF CHRONIC DISEASES TO EXPEDITE GROWTH 368   11.5 NURSING HOMES 370 11.5.1 GLOBAL SHIFT TOWARD AGED POPULATION TO STIMULATE GROWTH 370 11.6 OTHER END USERS 372 12 INJECTABLE DRUG DELIVERY MARKET, BY REGION 374 12.1 INTRODUCTION 375 12.2 NORTH AMERICA 376 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 376 12.2.2 US 391 12.2.2.1 Increasing prevalence of chronic diseases to expedite growth 391 12.2.3 CANADA 404 12.2.3.1 Growing preference for self-injection devices to drive market 404 12.3 EUROPE 417 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 417 12.3.2 GERMANY 430 12.3.2.1 High healthcare spending to propel growth 430 12.3.3 UK 443 12.3.3.1 Rising cases of obesity and diabetes to promote growth 443 12.3.4 FRANCE 456 12.3.4.1 Favorable health insurance system to accelerate growth 456 12.3.5 SPAIN 469 12.3.5.1 Favorable healthcare regulations support growth 469 12.3.6 ITALY 481 12.3.6.1 Regional variation in terms of coverage and benefits to hinder growth 481 12.3.7 NETHERLANDS 494 12.3.7.1 Growing focus on enhanced patient care to drive market 494 12.3.8 REST OF EUROPE 508 12.4 ASIA PACIFIC 521 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 521 12.4.2 CHINA 536 12.4.2.1 Large patient population and healthcare infrastructure improvements to augment growth 536 12.4.3 JAPAN 548 12.4.3.1 Supportive reimbursement policies and universal healthcare coverage to aid growth 548 12.4.4 INDIA 561 12.4.4.1 Rising diabetes and cardiovascular disease burden to propel market 561 12.4.5 AUSTRALIA 574 12.4.5.1 Increased patient volume to contribute to growth 574 12.4.6 SOUTH KOREA 587 12.4.6.1 Rising incidence of obesity and hypertension to amplify growth 587 12.4.7 THAILAND 600 12.4.7.1 Expanding self-administration options to support growth 600 12.4.8 VIETNAM 612 12.4.8.1 Rising investments and regulatory reforms to support market growth 612 12.4.9 REST OF ASIA PACIFIC 625 12.5 LATIN AMERICA 638 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 638 12.5.2 BRAZIL 652 12.5.2.1 Surge in obesity issues to stimulate growth 652 12.5.3 MEXICO 664 12.5.3.1 Increasing incidence of chronic diseases to drive market 664 12.5.4 REST OF LATIN AMERICA 677 12.6 MIDDLE EAST & AFRICA 690 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 690 12.6.2 GCC COUNTRIES 703 12.6.2.1 Saudi Arabia 717 12.6.2.1.1 Healthcare reforms to contribute to growth 717 12.6.2.2 United Arab Emirates (UAE) 730 12.6.2.2.1 Growing infrastructure investments to drive market 730 12.6.2.3 Rest of GCC Countries 743 12.6.3 REST OF MIDDLE EAST & AFRICA 756 13 COMPETITIVE LANDSCAPE 769 13.1 OVERVIEW 769 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 769 13.3 REVENUE ANALYSIS, 2020–2024 771 13.3.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS 771 13.3.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS 772 13.4 MARKET SHARE ANALYSIS, 2024 773 13.4.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS 773 13.4.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS 775 13.5 BRAND/PRODUCT COMPARISON 778 13.6 R&D EXPENDITURE OF KEY PLAYERS 778 13.7 COMPANY VALUATION AND FINANCIAL METRICS 779 13.7.1 COMPANY VALUATION 779 13.7.2 FINANCIAL METRICS 779 13.8 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 780 13.8.1 STARS 780 13.8.2 EMERGING LEADERS 780 13.8.3 PERVASIVE PLAYERS 780 13.8.4 PARTICIPANTS 780   13.8.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT, 2024 782 13.8.5.1 Company footprint 782 13.8.5.2 Region footprint 783 13.8.5.3 Product type footprint 783 13.8.5.4 Usage pattern footprint 784 13.8.5.5 Therapeutic application footprint 785 13.8.5.6 Site of administration footprint 786 13.9 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 787 13.9.1 PROGRESSIVE COMPANIES 787 13.9.2 RESPONSIVE COMPANIES 787 13.9.3 DYNAMIC COMPANIES 787 13.9.4 STARTING BLOCKS 787 13.9.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024 789 13.9.5.1 Detailed list of key startups/SMEs 789 13.9.5.2 Competitive benchmarking of startups/SMES 790 13.10 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 790 13.10.1 STARS 791 13.10.2 EMERGING LEADERS 791 13.10.3 PERVASIVE PLAYERS 791 13.10.4 PARTICIPANTS 791 13.10.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT, 2024 793 13.10.5.1 Company footprint 793 13.10.5.2 Region footprint 794 13.10.5.3 Product type footprint 795 13.10.5.4 Formulation packaging type footprint 796 13.10.5.5 Therapeutic application footprint 797 13.10.5.6 Site of administration footprint 798 13.11 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 799 13.11.1 PROGRESSIVE COMPANIES 799 13.11.2 RESPONSIVE COMPANIES 799 13.11.3 DYNAMIC COMPANIES 799 13.11.4 STARTING BLOCKS 799 13.11.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024 801 13.11.5.1 Detailed list of key startups/SMEs 801 13.11.5.2 Competitive benchmarking of startups/SMEs 802   13.12 COMPETITIVE SCENARIO 802 13.12.1 PRODUCT LAUNCHES AND APPROVALS 802 13.12.2 DEALS 803 13.12.3 EXPANSIONS 805 14 COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS 806 14.1 KEY PLAYERS 806 14.1.1 CARDINAL HEALTH 806 14.1.1.1 Business overview 806 14.1.1.2 Products offered 807 14.1.1.3 Recent developments 808 14.1.1.3.1 Expansions 808 14.1.1.4 MnM view 808 14.1.1.4.1 Right to win 808 14.1.1.4.2 Strategic choices 808 14.1.1.4.3 Weaknesses and competitive threats 809 14.1.2 BD 810 14.1.2.1 Business overview 810 14.1.2.2 Products offered 811 14.1.2.3 Recent developments 814 14.1.2.3.1 Deals 814 14.1.2.3.2 Expansions 815 14.1.2.4 MnM view 815 14.1.2.4.1 Right to win 815 14.1.2.4.2 Strategic choices 815 14.1.2.4.3 Weaknesses and competitive threats 815 14.1.3 B. BRAUN SE 816 14.1.3.1 Business overview 816 14.1.3.2 Products offered 817 14.1.3.3 MnM view 819 14.1.3.3.1 Right to win 819 14.1.3.3.2 Strategic choices 819 14.1.3.3.3 Weaknesses and competitive threats 819 14.1.4 BAXTER 820 14.1.4.1 Business overview 820 14.1.4.2 Products offered 821 14.1.4.3 Recent developments 822 14.1.4.3.1 Product launches and approvals 822 14.1.4.4 MnM view 823 14.1.4.4.1 Right to win 823 14.1.4.4.2 Strategic choices 823 14.1.4.4.3 Weaknesses and competitive threats 823 14.1.5 TERUMO CORPORATION 824 14.1.5.1 Business overview 824 14.1.5.2 Products offered 825 14.1.5.3 Recent developments 826 14.1.5.3.1 Product launches and approvals 826 14.1.5.3.2 Expansions 827 14.1.5.4 MnM view 827 14.1.5.4.1 Right to win 827 14.1.5.4.2 Strategic choices 827 14.1.5.4.3 Weaknesses and competitive threats 827 14.1.6 PHILLIPS-MEDSIZE CORPORATION (MOLEX) 828 14.1.6.1 Business overview 828 14.1.6.2 Products offered 828 14.1.6.3 Recent developments 829 14.1.6.3.1 Product launches and approvals 829 14.1.6.3.2 Deals 829 14.1.6.3.3 Expansions 829 14.1.7 NIPRO 830 14.1.7.1 Business overview 830 14.1.7.2 Products offered 831 14.1.7.3 Recent developments 832 14.1.7.3.1 Expansions 832 14.1.8 ICU MEDICAL, INC. 833 14.1.8.1 Business overview 833 14.1.8.2 Products offered 834 14.1.8.3 Recent developments 835 14.1.8.3.1 Deals 835 14.1.9 WEST PHARMACEUTICAL SERVICES, INC. 836 14.1.9.1 Business overview 836 14.1.9.2 Products offered 837 14.1.9.3 Recent developments 838 14.1.9.3.1 Deals 838 14.1.9.3.2 Expansions 838 14.1.10 GERRESHEIMER AG 840 14.1.10.1 Business overview 840 14.1.10.2 Products offered 841 14.1.10.3 Recent developments 843 14.1.10.3.1 Product launches and approvals 843 14.1.10.3.2 Deals 843 14.1.10.3.3 Expansions 844   14.1.11 STEVANATO 845 14.1.11.1 Business overview 845 14.1.11.2 Products offered 846 14.1.11.3 Recent developments 847 14.1.11.3.1 Product launches and approvals 847 14.1.11.3.2 Deals 847 14.1.11.3.3 Expansions 848 14.1.12 SCHOTT PHARMA 849 14.1.12.1 Business overview 849 14.1.12.2 Products offered 850 14.1.12.3 Recent developments 851 14.1.12.3.1 Product launches and approvals 851 14.1.12.3.2 Deals 851 14.1.12.3.3 Expansions 852 14.1.13 MEDMIX 853 14.1.13.1 Business overview 853 14.1.13.2 Products offered 854 14.1.13.3 Recent developments 855 14.1.13.3.1 Product launches and approvals 855 14.1.13.3.2 Deals 855 14.1.14 SOLM 856 14.1.14.1 Business overview 856 14.1.14.2 Products offered 856 14.1.15 YPSOMED 858 14.1.15.1 Business overview 858 14.1.15.2 Products offered 859 14.1.15.3 Recent developments 860 14.1.15.3.1 Deals 860 14.1.15.3.2 Expansions 861 14.2 OTHER PLAYERS 862 14.2.1 OWEN MUMFORD 862 14.2.2 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD. 863 14.2.3 POLYMEDICURE 864 14.2.4 UNION MEDICO INC. 865 14.2.5 SHL MEDICAL 866 14.2.6 ELCAM MEDICAL 867   15 COMPANY PROFILES: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS 868 15.1 KEY PLAYERS 868 15.1.1 JOHNSON & JOHNSON SERVICES, INC. 868 15.1.1.1 Business overview 868 15.1.1.2 Products offered 869 15.1.1.3 Recent developments 871 15.1.1.3.1 Product launches and approvals 871 15.1.1.3.2 Deals 873 15.1.1.4 MnM view 873 15.1.1.4.1 Right to win 873 15.1.1.4.2 Strategic choices 873 15.1.1.4.3 Weaknesses and competitive threats 873 15.1.2 F. HOFFMANN-LA ROCHE LTD 874 15.1.2.1 Business overview 874 15.1.2.2 Products offered 875 15.1.2.3 Recent developments 877 15.1.2.3.1 Product launches and approvals 877 15.1.2.4 MnM view 879 15.1.2.4.1 Right to win 879 15.1.2.4.2 Strategic choices 879 15.1.2.4.3 Weaknesses and competitive threats 879 15.1.3 PFIZER INC. 880 15.1.3.1 Business overview 880 15.1.3.2 Products offered 881 15.1.3.3 Recent developments 887 15.1.3.3.1 Product launches and approvals 887 15.1.3.3.2 Deals 888 15.1.3.4 MnM view 889 15.1.3.4.1 Right to win 889 15.1.3.4.2 Strategic choices 889 15.1.3.4.3 Weaknesses and competitive threats 889 15.1.4 MERCK & CO., INC. 890 15.1.4.1 Business overview 890 15.1.4.2 Products offered 891 15.1.4.3 Recent developments 893 15.1.4.3.1 Product launches and approvals 893 15.1.4.3.2 Deals 895 15.1.4.3.3 Expansions 896   15.1.4.4 MnM view 896 15.1.4.4.1 Right to win 896 15.1.4.4.2 Strategic choices 896 15.1.4.4.3 Weaknesses and competitive threats 897 15.1.5 NOVARTIS AG 898 15.1.5.1 Business overview 898 15.1.5.2 Products offered 899 15.1.5.3 Recent developments 900 15.1.5.3.1 Product launches and approvals 900 15.1.5.3.2 Deals 901 15.1.5.3.3 Expansions 902 15.1.5.4 MnM view 902 15.1.5.4.1 Right to win 902 15.1.5.4.2 Strategic choices 902 15.1.5.4.3 Weaknesses and competitive threats 902 15.1.6 BAYER AG 903 15.1.6.1 Business overview 903 15.1.6.2 Products offered 904 15.1.6.3 Recent developments 905 15.1.6.3.1 Product launches and approvals 905 15.1.6.3.2 Expansions 906 15.1.7 ASTRAZENECA 907 15.1.7.1 Business overview 907 15.1.7.2 Products offered 908 15.1.7.3 Recent developments 909 15.1.7.3.1 Product launches and approvals 909 15.1.7.3.2 Deals 914 15.1.7.3.3 Expansions 915 15.1.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 916 15.1.8.1 Business overview 916 15.1.8.2 Products offered 917 15.1.8.3 Recent developments 919 15.1.8.3.1 Product launches and approvals 919 15.1.8.3.2 Deals 921 15.1.8.3.3 Expansions 922 15.1.9 ELI LILLY AND COMPANY 923 15.1.9.1 Business overview 923 15.1.9.2 Products offered 924 15.1.9.3 Recent developments 925 15.1.9.3.1 Product launches and approvals 925 15.1.9.3.2 Expansions 926   15.1.10 AMGEN INC. 929 15.1.10.1 Business overview 929 15.1.10.2 Products offered 930 15.1.10.3 Recent developments 931 15.1.10.3.1 Product launches and approvals 931 15.1.10.3.2 Deals 932 15.1.10.3.3 Expansions 932 15.1.11 NOVO NORDISK A/S 934 15.1.11.1 Business overview 934 15.1.11.2 Products offered 935 15.1.11.3 Recent developments 936 15.1.11.3.1 Product launches and approvals 936 15.1.11.3.2 Deals 937 15.1.11.3.3 Expansions 937 15.1.12 REGENERON PHARMACEUTICALS INC. 939 15.1.12.1 Business overview 939 15.1.12.2 Products offered 940 15.1.12.2.1 Product launches and approvals 940 15.1.12.2.2 Deals 942 15.1.13 FRESENIUS KABI AG 943 15.1.13.1 Business overview 943 15.1.13.2 Products offered 944 15.1.13.3 Recent developments 945 15.1.13.3.1 Product launches and approvals 945 15.1.14 UCB S.A. 946 15.1.14.1 Business overview 946 15.1.14.2 Products offered 947 15.1.14.3 Recent developments 948 15.1.14.3.1 Product launches and approvals 948 15.1.15 BIO-THERA SOLUTIONS, LTD. 949 15.1.15.1 Business overview 949 15.1.15.2 Products offered 950 15.1.15.3 Recent developments 950 15.1.15.3.1 Product launches and approvals 950 15.2 OTHER PLAYERS 951 15.2.1 SAGENT 951 15.2.2 VALNEVA SE 954 15.2.3 XERIS PHARMACEUTICALS, INC. 955 15.2.4 PHARMAESSENTIA CORPORATION 956 15.2.5 HERON THERAPEUTICS, INC. 957   16 APPENDIX 958 16.1 DISCUSSION GUIDE 958 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 963 16.3 RELATED REPORTS 965 16.4 AUTHOR DETAILS 966
圖表清單 List of Tables & Figures
TABLE 1 INJECTABLE DRUG DELIVERY MARKET: INCLUSIONS AND EXCLUSIONS 75 TABLE 2 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD), 2021–2024 75 TABLE 3 INJECTABLE DRUG DELIVERY MARKET: STUDY ASSUMPTIONS 91 TABLE 4 INJECTABLE DRUG DELIVERY MARKET: RISK ASSESSMENT 92 TABLE 5 APPROVALS FOR AUTOINJECTOR BIOLOGICS BY US FDA, 2024 104 TABLE 6 KEY DEVELOPMENTS IN PREFILLED SYRINGES AND PEN INJECTORS, 2024–2025 104 TABLE 7 KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES 106 TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PLAYER, BY DEVICE TYPE, 2022–2024 (USD) 112 TABLE 9 AVERAGE SELLING PRICE TREND OF PEN INJECTORS, BY REGION, 2022–2024 (USD) 114 TABLE 10 AVERAGE SELLING PRICE TREND OF NEEDLE-FREE INJECTORS, BY REGION, 2022–2024 (USD) 114 TABLE 11 AVERAGE SELLING PRICE TREND OF AUTOINJECTORS, BY REGION, 2022–2024 (USD) 114 TABLE 12 AVERAGE SELLING PRICE TREND OF WEARABLE INJECTORS, BY REGION, 2022–2024 (USD) 115 TABLE 13 INJECTABLE DRUG DELIVERY DEVICE PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM 119 TABLE 14 INJECTABLE DRUG DELIVERY FORMULATION PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM 119 TABLE 15 INJECTABLE DRUG DELIVERY MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2025 125 TABLE 16 IMPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021–2024 (USD THOUSAND) 127 TABLE 17 EXPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021–2024 (USD THOUSAND) 127 TABLE 18 IMPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES), BY COUNTRY, 2021–2024 (USD THOUSAND) 128 TABLE 19 EXPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES), BY COUNTRY, 2021–2024 (USD THOUSAND) 128 TABLE 20 INJECTABLE DRUG DELIVERY MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 129 TABLE 21 CASE STUDY 1: DEVELOPMENT OF CLASS III DRUG DELIVERY SYSTEM FOR CHEMOTHERAPY 130 TABLE 22 CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION 131 TABLE 23 CASE STUDY 3: ADOPTION OF PEN INJECTOR PLATFORMS FOR IMPROVED THERAPEUTIC OUTCOMES 131 TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 133 TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 133 TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 134 TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 134 TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 135 TABLE 29 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 135 TABLE 30 INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 136 TABLE 31 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 138 TABLE 32 INJECTABLE DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE, 2023–2027 140 TABLE 33 US ADJUSTED RECIPROCAL TARIFF RATES, 2024 154 TABLE 34 KEY PRODUCT-RELATED TARIFF EFFECTIVE INJECTABLE DRUG DELIVERY DEVICES 154 TABLE 35 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS 155 TABLE 36 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS 156 TABLE 37 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS 157 TABLE 38 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS 157 TABLE 39 INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 160 TABLE 40 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 161 TABLE 41 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES 162 TABLE 42 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 164 TABLE 43 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 165 TABLE 44 KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES 166 TABLE 45 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 168 TABLE 46 CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 169 TABLE 47 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 170 TABLE 48 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 171 TABLE 49 KEY PLAYERS PROVIDING GLASS INJECTABLE DEVICES 172 TABLE 50 GLASS INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 173 TABLE 51 KEY PLAYERS PROVIDING PLASTIC INJECTABLE DEVICES 174 TABLE 52 PLASTIC INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 175 TABLE 53 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 176 TABLE 54 KEY PLAYERS PROVIDING FILLABLE SYRINGES 176 TABLE 55 FILLABLE SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 177 TABLE 56 KEY PLAYERS PROVIDING PREFILLED SYRINGES 178 TABLE 57 PREFILLED SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 179 TABLE 58 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 180 TABLE 59 KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES 180 TABLE 60 REUSABLE INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 181 TABLE 61 KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES 182 TABLE 62 DISPOSABLE INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 183 TABLE 63 KEY PLAYERS PROVIDING SELF-INJECTION DEVICES 184 TABLE 64 SELF-INJECTION DEVICES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 186 TABLE 65 SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 186 TABLE 66 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 187 TABLE 67 KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS 188 TABLE 68 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 189 TABLE 69 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 190 TABLE 70 NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 191 TABLE 71 KEY PLAYERS PROVIDING FILLABLE NEEDLE-FREE INJECTORS 191 TABLE 72 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 192 TABLE 73 KEY PLAYERS PROVIDING PREFILLED NEEDLE-FREE INJECTORS 193 TABLE 74 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 194 TABLE 75 NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 195 TABLE 76 KEY PLAYERS PROVIDING JET-BASED NEEDLE-FREE INJECTORS 195 TABLE 77 JET-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 196 TABLE 78 KEY PLAYERS PROVIDING SPRING-BASED NEEDLE-FREE INJECTORS 197 TABLE 79 SPRING-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 198 TABLE 80 KEY PLAYERS PROVIDING LASER-POWERED NEEDLE-FREE INJECTORS 199 TABLE 81 LASER-POWERED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 200 TABLE 82 VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 201 TABLE 83 NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 202 TABLE 84 KEY PLAYERS PROVIDING REUSABLE NEEDLE-FREE INJECTORS 202 TABLE 85 REUSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 203 TABLE 86 KEY PLAYERS PROVIDING DISPOSABLE NEEDLE-FREE INJECTORS 204 TABLE 87 DISPOSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 205 TABLE 88 KEY PLAYERS PROVIDING AUTOINJECTORS 206 TABLE 89 AUTOINJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 207 TABLE 90 AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 208 TABLE 91 AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 209 TABLE 92 KEY PLAYERS PROVIDING FILLABLE AUTOINJECTORS 209 TABLE 93 FILLABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 210 TABLE 94 KEY PLAYERS PROVIDING PREFILLED AUTOINJECTORS 211 TABLE 95 PREFILLED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 212 TABLE 96 AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 213 TABLE 97 KEY PLAYERS PROVIDING AUTOMATED AUTOINJECTORS 213 TABLE 98 AUTOMATED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 214 TABLE 99 KEY PLAYERS PROVIDING MANUAL AUTOINJECTORS 215 TABLE 100 MANUAL AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 216 TABLE 101 AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 217 TABLE 102 KEY PLAYERS PROVIDING STANDARDIZED AUTOINJECTORS 217 TABLE 103 STANDARDIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 218 TABLE 104 KEY PLAYERS PROVIDING CUSTOMIZED AUTOINJECTORS 219 TABLE 105 CUSTOMIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 220 TABLE 106 AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 221 TABLE 107 KEY PLAYERS PROVIDING REUSABLE AUTOINJECTORS 221 TABLE 108 REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 222 TABLE 109 KEY PLAYERS PROVIDING DISPOSABLE AUTOINJECTORS 223 TABLE 110 DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 224 TABLE 111 KEY PLAYERS PROVIDING PEN INJECTORS 225 TABLE 112 PEN INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 226 TABLE 113 PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 227 TABLE 114 PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 228 TABLE 115 KEY PLAYERS PROVIDING SINGLE-CHAMBERED PEN INJECTORS 228 TABLE 116 SINGLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 229 TABLE 117 KEY PLAYERS PROVIDING DOUBLE-CHAMBERED PEN INJECTORS 230 TABLE 118 DOUBLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 231 TABLE 119 PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 232 TABLE 120 KEY PLAYERS PROVIDING STANDARD PEN INJECTORS 232 TABLE 121 STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 233 TABLE 122 KEY PLAYERS PROVIDING CUSTOMIZED PEN INJECTORS 234 TABLE 123 CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 235 TABLE 124 PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 236 TABLE 125 KEY PLAYERS PROVIDING REUSABLE PEN INJECTORS 236 TABLE 126 REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 237 TABLE 127 KEY PLAYERS PROVIDING DISPOSABLE PEN INJECTORS 238 TABLE 128 DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 239 TABLE 129 KEY PLAYERS PROVIDING WEARABLE INJECTORS 240 TABLE 130 WEARABLE INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 241 TABLE 131 WEARABLE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 242 TABLE 132 KEY PLAYERS PROVIDING OTHER SELF-INJECTION DEVICES 243 TABLE 133 OTHER SELF-INJECTION DEVICES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 243 TABLE 134 OTHER SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 244 TABLE 135 KEY PLAYERS PROVIDING FORMULATIONS 245 TABLE 136 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 246 TABLE 137 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 247 TABLE 138 KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS 248 TABLE 139 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 249 TABLE 140 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 250 TABLE 141 KEY PLAYERS PROVIDING SOLUTIONS 251 TABLE 142 INJECTABLE DRUG DELIVERY SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 253 TABLE 143 KEY PLAYERS PROVIDING RECONSTITUTED/LYOPHILIZED FORMULATIONS 254 TABLE 144 RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 255 TABLE 145 KEY PLAYERS PROVIDING SUSPENSIONS 256 TABLE 146 INJECTABLE DRUG DELIVERY SUSPENSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 257 TABLE 147 KEY PLAYERS PROVIDING EMULSIONS 258 TABLE 148 INJECTABLE DRUG DELIVERY EMULSIONS MARKET, BY REGION, 2023–2030 (USD BILLION) 259 TABLE 149 KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS 260 TABLE 150 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 261 TABLE 151 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 262 TABLE 152 KEY PLAYERS PROVIDING COLLOIDAL DISPERSIONS 263 TABLE 153 COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 263 TABLE 154 COLLOIDAL DISPERSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 264 TABLE 155 INJECTABLE DRUG DELIVERY NIOSOMES MARKET, BY REGION, 2023–2030 (USD BILLION) 266 TABLE 156 KEY PLAYERS PROVIDING LIPOSOMES 267 TABLE 157 INJECTABLE DRUG DELIVERY LIPOSOMES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 268 TABLE 158 KEY PLAYERS PROVIDING POLYMERIC/MIXED MICELLES 269 TABLE 159 INJECTABLE DRUG DELIVERY POLYMERIC/MIXED MICELLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 270 TABLE 160 INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 271 TABLE 161 INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 272 TABLE 162 KEY PLAYERS PROVIDING SOLID-LIPID NANOPARTICLES 273 TABLE 163 INJECTABLE DRUG DELIVERY SOLID-LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 274 TABLE 164 KEY PLAYERS PROVIDING NANOSUSPENSIONS 275 TABLE 165 INJECTABLE DRUG DELIVERY NANOSUSPENSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 276 TABLE 166 KEY PLAYERS PROVIDING NANOEMULSIONS 277 TABLE 167 INJECTABLE DRUG DELIVERY NANOEMULSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 278 TABLE 168 KEY PLAYERS PROVIDING MICROPARTICLES 279 TABLE 169 INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 279 TABLE 170 INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 280 TABLE 171 KEY PLAYERS PROVIDING MICROSPHERES 281 TABLE 172 INJECTABLE DRUG DELIVERY MICROSPHERES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 282 TABLE 173 KEY PLAYERS PROVIDING MICROCAPSULES 283 TABLE 174 INJECTABLE DRUG DELIVERY MICROCAPSULES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 284 TABLE 175 KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS 285 TABLE 176 LONG-ACTING INJECTABLE FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 286 TABLE 177 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 288 TABLE 178 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY, 2023–2030 (USD BILLION) 289 TABLE 179 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY, 2023–2030 (USD BILLION) 291 TABLE 180 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY, 2023–2030 (USD BILLION) 293 TABLE 181 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY, 2023–2030 (USD BILLION) 295 TABLE 182 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 297 TABLE 183 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AUTOIMMUNE DISEASES 298 TABLE 184 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 299 TABLE 185 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 300 TABLE 186 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR RHEUMATOID ARTHRITIS 301 TABLE 187 INJECTABLE DRUG DELIVERY MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023–2030 (USD BILLION) 302 TABLE 188 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR MULTIPLE SCLEROSIS 303 TABLE 189 INJECTABLE DRUG DELIVERY MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023–2030 (USD BILLION) 304 TABLE 190 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CROHN’S DISEASE 305 TABLE 191 INJECTABLE DRUG DELIVERY MARKET FOR CROHN’S DISEASE, BY COUNTRY, 2023–2030 (USD BILLION) 306 TABLE 192 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PSORIASIS 307 TABLE 193 INJECTABLE DRUG DELIVERY MARKET FOR PSORIASIS, BY COUNTRY, 2023–2030 (USD BILLION) 308 TABLE 194 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER AUTOIMMUNE DISEASES 309 TABLE 195 INJECTABLE DRUG DELIVERY MARKET FOR OTHER AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 310 TABLE 196 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HORMONAL DISORDERS 311 TABLE 197 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 312 TABLE 198 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY COUNTRY, 2023–2030 (USD BILLION) 313 TABLE 199 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR DIABETES 314 TABLE 200 INJECTABLE DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION) 315 TABLE 201 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR REPRODUCTIVE HEALTH DISEASES 316 TABLE 202 INJECTABLE DRUG DELIVERY MARKET FOR REPRODUCTIVE HEALTH DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 317 TABLE 203 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY 318 TABLE 204 INJECTABLE DRUG DELIVERY MARKET FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY COUNTRY, 2023–2030 (USD BILLION) 319 TABLE 205 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OSTEOPOROSIS 320 TABLE 206 INJECTABLE DRUG DELIVERY MARKET FOR OSTEOPOROSIS, BY COUNTRY, 2023–2030 (USD BILLION) 321 TABLE 207 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR GROWTH HORMONE DEFICIENCY 322 TABLE 208 INJECTABLE DRUG DELIVERY MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2023–2030 (USD BILLION) 323 TABLE 209 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OBESITY 324 TABLE 210 INJECTABLE DRUG DELIVERY MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD BILLION) 325 TABLE 211 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CANCER 326 TABLE 212 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD BILLION) 328 TABLE 213 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR INFECTIOUS DISEASES 329 TABLE 214 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 330 TABLE 215 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ORPHAN DISEASES 331 TABLE 216 INJECTABLE DRUG DELIVERY MARKET FOR ORPHAN DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 332 TABLE 217 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER THERAPEUTIC APPLICATIONS 333 TABLE 218 INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 334 TABLE 219 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PAIN MANAGEMENT 335 TABLE 220 INJECTABLE DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION) 336 TABLE 221 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ALLERGIES 337 TABLE 222 INJECTABLE DRUG DELIVERY MARKET FOR ALLERGIES, BY COUNTRY, 2023–2030 (USD BILLION) 338 TABLE 223 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AESTHETIC TREATMENTS 339 TABLE 224 INJECTABLE DRUG DELIVERY MARKET FOR AESTHETIC TREATMENTS, BY COUNTRY, 2023–2030 (USD BILLION) 340 TABLE 225 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEPATITIS C 341 TABLE 226 INJECTABLE DRUG DELIVERY MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD BILLION) 342 TABLE 227 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEMOPHILIA 343 TABLE 228 INJECTABLE DRUG DELIVERY MARKET FOR HEMOPHILIA, BY COUNTRY, 2023–2030 (USD BILLION) 344 TABLE 229 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 346 TABLE 230 INJECTABLE DRUG DELIVERY MARKET FOR CURATIVE CARE, BY COUNTRY, 2023–2030 (USD BILLION) 347 TABLE 231 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNIZATION, BY COUNTRY, 2023–2030 (USD BILLION) 349 TABLE 232 INJECTABLE DRUG DELIVERY MARKET FOR OTHER USAGE PATTERNS, BY COUNTRY, 2023–2030 (USD BILLION) 351 TABLE 233 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 353 TABLE 234 KEY PLAYERS PROVIDING DERMAL-BASED ADMINISTRATION 354 TABLE 235 INJECTABLE DRUG DELIVERY MARKET FOR DERMAL-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION) 355 TABLE 236 KEY PLAYERS PROVIDING CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION 356 TABLE 237 INJECTABLE DRUG DELIVERY MARKET FOR CIRCULATORY/MUSCULOSKELETAL-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION) 358 TABLE 238 KEY PLAYERS PROVIDING ORGAN-BASED ADMINISTRATION 359 TABLE 239 INJECTABLE DRUG DELIVERY MARKET FOR ORGAN-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION) 360 TABLE 240 KEY PLAYERS PROVIDING CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION 361 TABLE 241 INJECTABLE DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION) 362 TABLE 242 INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 364 TABLE 243 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION) 365 TABLE 244 INJECTABLE DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION) 367 TABLE 245 INJECTABLE DRUG DELIVERY MARKET FOR LONG-TERM CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION) 369 TABLE 246 INJECTABLE DRUG DELIVERY MARKET FOR NURSING HOMES, BY COUNTRY, 2023–2030 (USD BILLION) 371 TABLE 247 INJECTABLE DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 373 TABLE 248 INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION) 376 TABLE 249 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 378 TABLE 250 NORTH AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 378 TABLE 251 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 378 TABLE 252 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 379 TABLE 253 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 379 TABLE 254 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 379 TABLE 255 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 380 TABLE 256 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 380 TABLE 257 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 381 TABLE 258 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 381 TABLE 259 NORTH AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 382 TABLE 260 NORTH AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 382 TABLE 261 NORTH AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 382 TABLE 262 NORTH AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 383 TABLE 263 NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 383 TABLE 264 NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 383 TABLE 265 NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 384 TABLE 266 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 384 TABLE 267 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 385 TABLE 268 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 385 TABLE 269 NORTH AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 386 TABLE 270 NORTH AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 386 TABLE 271 NORTH AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 386 TABLE 272 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 387 TABLE 273 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 387 TABLE 274 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 388 TABLE 275 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 388 TABLE 276 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 389 TABLE 277 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 389 TABLE 278 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 390 TABLE 279 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 390 TABLE 280 US: KEY MACROECONOMIC INDICATORS 391 TABLE 281 US: INJECTABLE DRUG DELIVERY MARKET PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 392 TABLE 282 US: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 392 TABLE 283 US: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 392 TABLE 284 US: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 393 TABLE 285 US: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 393 TABLE 286 US: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 393 TABLE 287 US: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 394 TABLE 288 US: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 394 TABLE 289 US: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 394 TABLE 290 US: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 395 TABLE 291 US: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 395 TABLE 292 US: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 395 TABLE 293 US: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 396 TABLE 294 US: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 396 TABLE 295 US: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 396 TABLE 296 US: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 397 TABLE 297 US: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 397 TABLE 298 US: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 398 TABLE 299 US: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 398 TABLE 300 US: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 399 TABLE 301 US: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 399 TABLE 302 US: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 399 TABLE 303 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 400 TABLE 304 US: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 400 TABLE 305 US: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 401 TABLE 306 US: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 401 TABLE 307 US: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 402 TABLE 308 US: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 402 TABLE 309 US: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 403 TABLE 310 US: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 403 TABLE 311 CANADA: KEY MACROECONOMIC INDICATORS 404 TABLE 312 CANADA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 405 TABLE 313 CANADA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 405 TABLE 314 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 405 TABLE 315 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 406 TABLE 316 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 406 TABLE 317 CANADA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 406 TABLE 318 CANADA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 407 TABLE 319 CANADA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 407 TABLE 320 CANADA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 407 TABLE 321 CANADA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 408 TABLE 322 CANADA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 408 TABLE 323 CANADA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 408 TABLE 324 CANADA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 409 TABLE 325 CANADA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 409 TABLE 326 CANADA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 409 TABLE 327 CANADA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 410 TABLE 328 CANADA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 410 TABLE 329 CANADA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 411 TABLE 330 CANADA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 411 TABLE 331 CANADA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 412 TABLE 332 CANADA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 412 TABLE 333 CANADA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 412 TABLE 334 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 413 TABLE 335 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 413 TABLE 336 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2030 (USD BILLION) 414 TABLE 337 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 414 TABLE 338 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 415 TABLE 339 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 415 TABLE 340 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 416 TABLE 341 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 416 TABLE 342 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 418 TABLE 343 EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 418 TABLE 344 EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 419 TABLE 345 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 419 TABLE 346 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 419 TABLE 347 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 420 TABLE 348 EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 420 TABLE 349 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 420 TABLE 350 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 421 TABLE 351 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 421 TABLE 352 EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 421 TABLE 353 EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 422 TABLE 354 EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 422 TABLE 355 EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 422 TABLE 356 EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 423 TABLE 357 EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 423 TABLE 358 EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 423 TABLE 359 EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 424 TABLE 360 EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 424 TABLE 361 EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 425 TABLE 362 EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 425 TABLE 363 EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 425 TABLE 364 EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 426 TABLE 365 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 426 TABLE 366 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 427 TABLE 367 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 427 TABLE 368 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 428 TABLE 369 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 428 TABLE 370 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 429 TABLE 371 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 429 TABLE 372 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 430 TABLE 373 GERMANY: KEY MACROECONOMIC INDICATORS 431 TABLE 374 GERMANY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 431 TABLE 375 GERMANY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 431 TABLE 376 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 432 TABLE 377 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 432 TABLE 378 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 432 TABLE 379 GERMANY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 433 TABLE 380 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 433 TABLE 381 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 434 TABLE 382 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 434 TABLE 383 GERMANY: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 434 TABLE 384 GERMANY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 435 TABLE 385 GERMANY: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 435 TABLE 386 GERMANY: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 435 TABLE 387 GERMANY: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 436 TABLE 388 GERMANY: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 436 TABLE 389 GERMANY: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 436 TABLE 390 GERMANY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 437 TABLE 391 GERMANY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 437 TABLE 392 GERMANY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 438 TABLE 393 GERMANY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 438 TABLE 394 GERMANY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 438 TABLE 395 GERMANY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 439 TABLE 396 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 439 TABLE 397 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 440 TABLE 398 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 440 TABLE 399 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 441 TABLE 400 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 441 TABLE 401 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 442 TABLE 402 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 442 TABLE 403 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 443 TABLE 404 UK: KEY MACROECONOMIC INDICATORS 444 TABLE 405 UK: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 444 TABLE 406 UK: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 444 TABLE 407 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 445 TABLE 408 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 445 TABLE 409 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 445 TABLE 410 UK: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 446 TABLE 411 UK: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 446 TABLE 412 UK: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 447 TABLE 413 UK: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 447 TABLE 414 UK: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 447 TABLE 415 UK: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 448 TABLE 416 UK: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 448 TABLE 417 UK: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 448 TABLE 418 UK: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 449 TABLE 419 UK: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 449 TABLE 420 UK: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 449 TABLE 421 UK: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 450 TABLE 422 UK: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 450 TABLE 423 UK: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 451 TABLE 424 UK: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 451 TABLE 425 UK: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 451 TABLE 426 UK: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 452 TABLE 427 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 452 TABLE 428 UK: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 453 TABLE 429 UK: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 453 TABLE 430 UK: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 454 TABLE 431 UK: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 454 TABLE 432 UK: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 455 TABLE 433 UK: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 455 TABLE 434 UK: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 456 TABLE 435 FRANCE: KEY MACROECONOMIC INDICATORS 456 TABLE 436 FRANCE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 457 TABLE 437 FRANCE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 457 TABLE 438 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 457 TABLE 439 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 458 TABLE 440 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 458 TABLE 441 FRANCE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 458 TABLE 442 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 459 TABLE 443 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 459 TABLE 444 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 459 TABLE 445 FRANCE: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 460 TABLE 446 FRANCE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 460 TABLE 447 FRANCE: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 460 TABLE 448 FRANCE: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 461 TABLE 449 FRANCE: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 461 TABLE 450 FRANCE: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 461 TABLE 451 FRANCE: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 462 TABLE 452 FRANCE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 462 TABLE 453 FRANCE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 463 TABLE 454 FRANCE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 463 TABLE 455 FRANCE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 464 TABLE 456 FRANCE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 464 TABLE 457 FRANCE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 464 TABLE 458 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 465 TABLE 459 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 465 TABLE 460 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 466 TABLE 461 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 466 TABLE 462 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 467 TABLE 463 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 467 TABLE 464 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 468 TABLE 465 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 468 TABLE 466 SPAIN: KEY MACROECONOMIC INDICATORS 469 TABLE 467 SPAIN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 469 TABLE 468 SPAIN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 470 TABLE 469 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 470 TABLE 470 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 470 TABLE 471 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 471 TABLE 472 SPAIN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 471 TABLE 473 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 471 TABLE 474 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 472 TABLE 475 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 472 TABLE 476 SPAIN: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 472 TABLE 477 SPAIN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 473 TABLE 478 SPAIN: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 473 TABLE 479 SPAIN: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 473 TABLE 480 SPAIN: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 474 TABLE 481 SPAIN: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 474 TABLE 482 SPAIN: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 474 TABLE 483 SPAIN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 475 TABLE 484 SPAIN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 475 TABLE 485 SPAIN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 476 TABLE 486 SPAIN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 476 TABLE 487 SPAIN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 476 TABLE 488 SPAIN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 477 TABLE 489 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 477 TABLE 490 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 478 TABLE 491 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 478 TABLE 492 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 479 TABLE 493 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 479 TABLE 494 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 480 TABLE 495 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 480 TABLE 496 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 481 TABLE 497 ITALY: KEY MACROECONOMIC INDICATORS 482 TABLE 498 ITALY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 482 TABLE 499 ITALY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 482 TABLE 500 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 483 TABLE 501 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 483 TABLE 502 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 483 TABLE 503 ITALY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 484 TABLE 504 ITALY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 484 TABLE 505 ITALY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 485 TABLE 506 ITALY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 485 TABLE 507 ITALY: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 485 TABLE 508 ITALY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 486 TABLE 509 ITALY: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 486 TABLE 510 ITALY: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 486 TABLE 511 ITALY: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 487 TABLE 512 ITALY: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 487 TABLE 513 ITALY: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 487 TABLE 514 ITALY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 488 TABLE 515 ITALY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 488 TABLE 516 ITALY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 489 TABLE 517 ITALY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 489 TABLE 518 ITALY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 489 TABLE 519 ITALY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 490 TABLE 520 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 490 TABLE 521 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 491 TABLE 522 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 491 TABLE 523 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 492 TABLE 524 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 492 TABLE 525 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 493 TABLE 526 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 493 TABLE 527 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 494 TABLE 528 NETHERLANDS: KEY MACROECONOMIC INDICATORS 495 TABLE 529 NETHERLANDS: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 495 TABLE 530 NETHERLANDS: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 495 TABLE 531 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 496 TABLE 532 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 496 TABLE 533 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 496 TABLE 534 NETHERLANDS: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 497 TABLE 535 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 497 TABLE 536 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 498 TABLE 537 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 498 TABLE 538 NETHERLANDS: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 499 TABLE 539 NETHERLANDS: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 499 TABLE 540 NETHERLANDS: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 499 TABLE 541 NETHERLANDS: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 500 TABLE 542 NETHERLANDS: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 500 TABLE 543 NETHERLANDS: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 500 TABLE 544 NETHERLANDS: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 501 TABLE 545 NETHERLANDS: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 501 TABLE 546 NETHERLANDS: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 502 TABLE 547 NETHERLANDS: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 502 TABLE 548 NETHERLANDS: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 503 TABLE 549 NETHERLANDS: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 503 TABLE 550 NETHERLANDS: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 503 TABLE 551 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 504 TABLE 552 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 504 TABLE 553 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 505 TABLE 554 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 505 TABLE 555 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 506 TABLE 556 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 506 TABLE 557 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 507 TABLE 558 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 507 TABLE 559 REST OF EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 508 TABLE 560 REST OF EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 508 TABLE 561 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 509 TABLE 562 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 509 TABLE 563 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 509 TABLE 564 REST OF EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 510 TABLE 565 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 510 TABLE 566 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 511 TABLE 567 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 511 TABLE 568 REST OF EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 512 TABLE 569 REST OF EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 512 TABLE 570 REST OF EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 512 TABLE 571 REST OF EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 513 TABLE 572 REST OF EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 513 TABLE 573 REST OF EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 513 TABLE 574 REST OF EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 514 TABLE 575 REST OF EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 514 TABLE 576 REST OF EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 515 TABLE 577 REST OF EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 515 TABLE 578 REST OF EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 516 TABLE 579 REST OF EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 516 TABLE 580 REST OF EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 516 TABLE 581 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 517 TABLE 582 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 517 TABLE 583 REST OF EUROPE: INJECTABLE DRUG DELIVERY FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 518 TABLE 584 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 518 TABLE 585 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 519 TABLE 586 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 519 TABLE 587 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 520 TABLE 588 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 520 TABLE 589 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 523 TABLE 590 ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 523 TABLE 591 ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 524 TABLE 592 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 524 TABLE 593 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 524 TABLE 594 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 525 TABLE 595 ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 525 TABLE 596 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 525 TABLE 597 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 526 TABLE 598 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 526 TABLE 599 ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 527 TABLE 600 ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 527 TABLE 601 ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 527 TABLE 602 ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 528 TABLE 603 ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 528 TABLE 604 ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 528 TABLE 605 ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 529 TABLE 606 ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 529 TABLE 607 ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 530 TABLE 608 ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 530 TABLE 609 ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 531 TABLE 610 ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 531 TABLE 611 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 531 TABLE 612 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 532 TABLE 613 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 532 TABLE 614 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 533 TABLE 615 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 533 TABLE 616 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 534 TABLE 617 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 534 TABLE 618 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 535 TABLE 619 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 535 TABLE 620 CHINA: KEY MACROECONOMIC INDICATORS 536 TABLE 621 CHINA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 536 TABLE 622 CHINA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 537 TABLE 623 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 537 TABLE 624 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 537 TABLE 625 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 538 TABLE 626 CHINA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 538 TABLE 627 CHINA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 538 TABLE 628 CHINA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 539 TABLE 629 CHINA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 539 TABLE 630 CHINA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 539 TABLE 631 CHINA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 540 TABLE 632 CHINA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 540 TABLE 633 CHINA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 540 TABLE 634 CHINA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 541 TABLE 635 CHINA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 541 TABLE 636 CHINA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 541 TABLE 637 CHINA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 542 TABLE 638 CHINA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 542 TABLE 639 CHINA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 543 TABLE 640 CHINA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 543 TABLE 641 CHINA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 543 TABLE 642 CHINA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 544 TABLE 643 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 544 TABLE 644 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 545 TABLE 645 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 545 TABLE 646 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 546 TABLE 647 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 546 TABLE 648 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 547 TABLE 649 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 547 TABLE 650 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 548 TABLE 651 JAPAN: KEY MACROECONOMIC INDICATORS 549 TABLE 652 JAPAN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 549 TABLE 653 JAPAN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 549 TABLE 654 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 550 TABLE 655 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 550 TABLE 656 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 550 TABLE 657 JAPAN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 551 TABLE 658 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 551 TABLE 659 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 552 TABLE 660 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 552 TABLE 661 JAPAN: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 552 TABLE 662 JAPAN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 553 TABLE 663 JAPAN: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 553 TABLE 664 JAPAN: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 553 TABLE 665 JAPAN: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 554 TABLE 666 JAPAN: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 554 TABLE 667 JAPAN: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 554 TABLE 668 JAPAN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 555 TABLE 669 JAPAN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 555 TABLE 670 JAPAN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 556 TABLE 671 JAPAN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 556 TABLE 672 JAPAN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 556 TABLE 673 JAPAN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 557 TABLE 674 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 557 TABLE 675 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 558 TABLE 676 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 558 TABLE 677 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 559 TABLE 678 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 559 TABLE 679 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 560 TABLE 680 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 560 TABLE 681 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 561 TABLE 682 INDIA: KEY MACROECONOMIC INDICATORS 561 TABLE 683 INDIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 562 TABLE 684 INDIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 562 TABLE 685 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 562 TABLE 686 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 563 TABLE 687 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 563 TABLE 688 INDIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 563 TABLE 689 INDIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 564 TABLE 690 INDIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 564 TABLE 691 INDIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 564 TABLE 692 INDIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 565 TABLE 693 INDIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 565 TABLE 694 INDIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 565 TABLE 695 INDIA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 566 TABLE 696 INDIA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 566 TABLE 697 INDIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 566 TABLE 698 INDIA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 567 TABLE 699 INDIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 567 TABLE 700 INDIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 568 TABLE 701 INDIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 568 TABLE 702 INDIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 569 TABLE 703 INDIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 569 TABLE 704 INDIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 569 TABLE 705 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 570 TABLE 706 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 570 TABLE 707 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 571 TABLE 708 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 571 TABLE 709 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 572 TABLE 710 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 572 TABLE 711 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 573 TABLE 712 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 573 TABLE 713 AUSTRALIA: KEY MACROECONOMIC INDICATORS 574 TABLE 714 AUSTRALIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 574 TABLE 715 AUSTRALIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 575 TABLE 716 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 575 TABLE 717 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 575 TABLE 718 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 576 TABLE 719 AUSTRALIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 576 TABLE 720 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 576 TABLE 721 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 577 TABLE 722 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 577 TABLE 723 AUSTRALIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 578 TABLE 724 AUSTRALIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 578 TABLE 725 AUSTRALIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 578 TABLE 726 AUSTRALIA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 579 TABLE 727 AUSTRALIA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 579 TABLE 728 AUSTRALIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 579 TABLE 729 AUSTRALIA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 580 TABLE 730 AUSTRALIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 580 TABLE 731 AUSTRALIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 581 TABLE 732 AUSTRALIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 581 TABLE 733 AUSTRALIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 582 TABLE 734 AUSTRALIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 582 TABLE 735 AUSTRALIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 582 TABLE 736 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 583 TABLE 737 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 583 TABLE 738 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 584 TABLE 739 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 584 TABLE 740 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 585 TABLE 741 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 585 TABLE 742 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 586 TABLE 743 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 586 TABLE 744 SOUTH KOREA: KEY MACROECONOMIC INDICATORS 587 TABLE 745 SOUTH KOREA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, TYPE, 2023–2030 (USD BILLION) 588 TABLE 746 SOUTH KOREA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 588 TABLE 747 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 588 TABLE 748 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 589 TABLE 749 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 589 TABLE 750 SOUTH KOREA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 589 TABLE 751 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 590 TABLE 752 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 590 TABLE 753 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 591 TABLE 754 SOUTH KOREA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 591 TABLE 755 SOUTH KOREA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 591 TABLE 756 SOUTH KOREA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 592 TABLE 757 SOUTH KOREA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 592 TABLE 758 SOUTH KOREA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 592 TABLE 759 SOUTH KOREA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 593 TABLE 760 SOUTH KOREA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 593 TABLE 761 SOUTH KOREA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 593 TABLE 762 SOUTH KOREA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 594 TABLE 763 SOUTH KOREA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 594 TABLE 764 SOUTH KOREA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 595 TABLE 765 SOUTH KOREA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 595 TABLE 766 SOUTH KOREA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 595 TABLE 767 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 596 TABLE 768 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 596 TABLE 769 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 597 TABLE 770 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 597 TABLE 771 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 598 TABLE 772 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 598 TABLE 773 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 599 TABLE 774 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 599 TABLE 775 THAILAND: KEY MACROECONOMIC INDICATORS 600 TABLE 776 THAILAND: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 600 TABLE 777 THAILAND: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 601 TABLE 778 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 601 TABLE 779 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 601 TABLE 780 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 602 TABLE 781 THAILAND: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 602 TABLE 782 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 602 TABLE 783 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 603 TABLE 784 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 603 TABLE 785 THAILAND: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 603 TABLE 786 THAILAND: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 604 TABLE 787 THAILAND: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 604 TABLE 788 THAILAND: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 604 TABLE 789 THAILAND: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 605 TABLE 790 THAILAND: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 605 TABLE 791 THAILAND: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 605 TABLE 792 THAILAND: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 606 TABLE 793 THAILAND: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 606 TABLE 794 THAILAND: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 607 TABLE 795 THAILAND: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 607 TABLE 796 THAILAND: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 607 TABLE 797 THAILAND: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 608 TABLE 798 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 608 TABLE 799 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 609 TABLE 800 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 609 TABLE 801 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 610 TABLE 802 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 610 TABLE 803 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 611 TABLE 804 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 611 TABLE 805 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 612 TABLE 806 VIETNAM: KEY MACROECONOMIC INDICATORS 613 TABLE 807 VIETNAM: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 613 TABLE 808 VIETNAM: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 613 TABLE 809 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 614 TABLE 810 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 614 TABLE 811 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 614 TABLE 812 VIETNAM: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 615 TABLE 813 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 615 TABLE 814 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 616 TABLE 815 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 616 TABLE 816 VIETNAM: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 616 TABLE 817 VIETNAM: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 617 TABLE 818 VIETNAM: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 617 TABLE 819 VIETNAM: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 617 TABLE 820 VIETNAM: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 618 TABLE 821 VIETNAM: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 618 TABLE 822 VIETNAM: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 618 TABLE 823 VIETNAM: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 619 TABLE 824 VIETNAM: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 619 TABLE 825 VIETNAM: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 620 TABLE 826 VIETNAM: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 620 TABLE 827 VIETNAM: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 620 TABLE 828 VIETNAM: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 621 TABLE 829 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 621 TABLE 830 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 622 TABLE 831 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 622 TABLE 832 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 623 TABLE 833 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 623 TABLE 834 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 624 TABLE 835 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 624 TABLE 836 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 625 TABLE 837 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 625 TABLE 838 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 626 TABLE 839 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 626 TABLE 840 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 626 TABLE 841 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 627 TABLE 842 REST OF ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 627 TABLE 843 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 627 TABLE 844 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 628 TABLE 845 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 628 TABLE 846 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 629 TABLE 847 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 629 TABLE 848 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 629 TABLE 849 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 630 TABLE 850 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 630 TABLE 851 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 630 TABLE 852 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 631 TABLE 853 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 631 TABLE 854 REST OF ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 632 TABLE 855 REST OF ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 632 TABLE 856 REST OF ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 633 TABLE 857 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 633 TABLE 858 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 633 TABLE 859 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 634 TABLE 860 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 634 TABLE 861 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 635 TABLE 862 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 635 TABLE 863 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 636 TABLE 864 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 636 TABLE 865 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 637 TABLE 866 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 637 TABLE 867 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 639 TABLE 868 LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 639 TABLE 869 LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 639 TABLE 870 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 640 TABLE 871 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 640 TABLE 872 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 640 TABLE 873 LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 641 TABLE 874 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 641 TABLE 875 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 642 TABLE 876 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 642 TABLE 877 LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 643 TABLE 878 LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 643 TABLE 879 LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 643 TABLE 880 LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 644 TABLE 881 LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 644 TABLE 882 LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 644 TABLE 883 LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 645 TABLE 884 LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 645 TABLE 885 LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 646 TABLE 886 LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 646 TABLE 887 LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 647 TABLE 888 LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 647 TABLE 889 LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 647 TABLE 890 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 648 TABLE 891 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 648 TABLE 892 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 649 TABLE 893 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 649 TABLE 894 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 650 TABLE 895 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 650 TABLE 896 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 651 TABLE 897 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 651 TABLE 898 BRAZIL: KEY MACROECONOMIC INDICATORS 652 TABLE 899 BRAZIL: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 652 TABLE 900 BRAZIL: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 653 TABLE 901 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 653 TABLE 902 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 653 TABLE 903 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 654 TABLE 904 BRAZIL: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 654 TABLE 905 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 654 TABLE 906 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 655 TABLE 907 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 655 TABLE 908 BRAZIL: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 655 TABLE 909 BRAZIL: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 656 TABLE 910 BRAZIL: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 656 TABLE 911 BRAZIL: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 656 TABLE 912 BRAZIL: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 657 TABLE 913 BRAZIL: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 657 TABLE 914 BRAZIL: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 657 TABLE 915 BRAZIL: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 658 TABLE 916 BRAZIL: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 658 TABLE 917 BRAZIL: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 659 TABLE 918 BRAZIL: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 659 TABLE 919 BRAZIL: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 659 TABLE 920 BRAZIL: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 660 TABLE 921 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 660 TABLE 922 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 661 TABLE 923 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 661 TABLE 924 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 662 TABLE 925 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 662 TABLE 926 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 663 TABLE 927 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 663 TABLE 928 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 664 TABLE 929 MEXICO: KEY MACROECONOMIC INDICATORS 664 TABLE 930 MEXICO: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 665 TABLE 931 MEXICO: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 665 TABLE 932 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 665 TABLE 933 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 666 TABLE 934 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 666 TABLE 935 MEXICO: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 666 TABLE 936 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 667 TABLE 937 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 667 TABLE 938 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 667 TABLE 939 MEXICO: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 668 TABLE 940 MEXICO: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 668 TABLE 941 MEXICO: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 668 TABLE 942 MEXICO: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 669 TABLE 943 MEXICO: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 669 TABLE 944 MEXICO: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 669 TABLE 945 MEXICO: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 670 TABLE 946 MEXICO: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 670 TABLE 947 MEXICO: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 671 TABLE 948 MEXICO: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 671 TABLE 949 MEXICO: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 672 TABLE 950 MEXICO: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 672 TABLE 951 MEXICO: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 672 TABLE 952 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 673 TABLE 953 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 673 TABLE 954 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 674 TABLE 955 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 674 TABLE 956 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 675 TABLE 957 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 675 TABLE 958 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 676 TABLE 959 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 676 TABLE 960 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 677 TABLE 961 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 677 TABLE 962 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 678 TABLE 963 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 678 TABLE 964 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 678 TABLE 965 REST OF LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 679 TABLE 966 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 679 TABLE 967 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 680 TABLE 968 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 680 TABLE 969 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 681 TABLE 970 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 681 TABLE 971 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 681 TABLE 972 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 682 TABLE 973 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 682 TABLE 974 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 682 TABLE 975 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 683 TABLE 976 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 683 TABLE 977 REST OF LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 684 TABLE 978 REST OF LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 684 TABLE 979 REST OF LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 685 TABLE 980 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 685 TABLE 981 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 685 TABLE 982 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 686 TABLE 983 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 686 TABLE 984 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 687 TABLE 985 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 687 TABLE 986 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 688 TABLE 987 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 688 TABLE 988 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 689 TABLE 989 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 689 TABLE 990 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION) 691 TABLE 991 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 691 TABLE 992 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 691 TABLE 993 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 692 TABLE 994 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 692 TABLE 995 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 692 TABLE 996 MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 693 TABLE 997 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 693 TABLE 998 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 694 TABLE 999 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 694 TABLE 1000 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 695 TABLE 1001 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 695 TABLE 1002 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 695 TABLE 1003 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 696 TABLE 1004 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 696 TABLE 1005 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 696 TABLE 1006 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 697 TABLE 1007 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 697 TABLE 1008 MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 697 TABLE 1009 MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 698 TABLE 1010 MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 698 TABLE 1011 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 698 TABLE 1012 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 699 TABLE 1013 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 699 TABLE 1014 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 700 TABLE 1015 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 700 TABLE 1016 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 701 TABLE 1017 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 701 TABLE 1018 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 702 TABLE 1019 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 702 TABLE 1020 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 703 TABLE 1021 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 704 TABLE 1022 GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 704 TABLE 1023 GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 704 TABLE 1024 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 705 TABLE 1025 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 705 TABLE 1026 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 705 TABLE 1027 GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 706 TABLE 1028 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 706 TABLE 1029 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 707 TABLE 1030 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 707 TABLE 1031 GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 708 TABLE 1032 GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 708 TABLE 1033 GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 708 TABLE 1034 GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 709 TABLE 1035 GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 709 TABLE 1036 GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 709 TABLE 1037 GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 710 TABLE 1038 GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 710 TABLE 1039 GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 711 TABLE 1040 GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 711 TABLE 1041 GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 712 TABLE 1042 GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 712 TABLE 1043 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 712 TABLE 1044 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 713 TABLE 1045 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 713 TABLE 1046 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 714 TABLE 1047 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 714 TABLE 1048 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 715 TABLE 1049 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 715 TABLE 1050 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 716 TABLE 1051 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 716 TABLE 1052 SAUDI ARABIA: KEY MACROECONOMIC INDICATORS 717 TABLE 1053 SAUDI ARABIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 717 TABLE 1054 SAUDI ARABIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 718 TABLE 1055 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 718 TABLE 1056 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 718 TABLE 1057 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 719 TABLE 1058 SAUDI ARABIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 719 TABLE 1059 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 719 TABLE 1060 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 720 TABLE 1061 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 720 TABLE 1062 SAUDI ARABIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 721 TABLE 1063 SAUDI ARABIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 721 TABLE 1064 SAUDI ARABIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 721 TABLE 1065 SAUDI ARABIA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 722 TABLE 1066 SAUDI ARABIA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 722 TABLE 1067 SAUDI ARABIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 722 TABLE 1068 SAUDI ARABIA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 723 TABLE 1069 SAUDI ARABIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 723 TABLE 1070 SAUDI ARABIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 724 TABLE 1071 SAUDI ARABIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 724 TABLE 1072 SAUDI ARABIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 725 TABLE 1073 SAUDI ARABIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 725 TABLE 1074 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 725 TABLE 1075 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 726 TABLE 1076 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 726 TABLE 1077 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 727 TABLE 1078 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 727 TABLE 1079 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 728 TABLE 1080 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 728 TABLE 1081 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 729 TABLE 1082 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 729 TABLE 1083 UNITED ARAB EMIRATES (UAE): KEY MACROECONOMIC INDICATORS 730 TABLE 1084 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 730 TABLE 1085 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 731 TABLE 1086 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 731 TABLE 1087 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 731 TABLE 1088 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 732 TABLE 1089 UNITED ARAB EMIRATES (UAE): SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 732 TABLE 1090 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 732 TABLE 1091 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 733 TABLE 1092 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 733 TABLE 1093 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 734 TABLE 1094 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 734 TABLE 1095 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 734 TABLE 1096 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 735 TABLE 1097 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 735 TABLE 1098 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 735 TABLE 1099 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 736 TABLE 1100 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 736 TABLE 1101 UNITED ARAB EMIRATES (UAE): CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 737 TABLE 1102 UNITED ARAB EMIRATES (UAE): NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 737 TABLE 1103 UNITED ARAB EMIRATES (UAE): COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 738 TABLE 1104 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 738 TABLE 1105 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 738 TABLE 1106 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 739 TABLE 1107 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 739 TABLE 1108 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 740 TABLE 1109 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 740 TABLE 1110 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 741 TABLE 1111 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 741 TABLE 1112 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 742 TABLE 1113 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 742 TABLE 1114 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 743 TABLE 1115 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 743 TABLE 1116 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 744 TABLE 1117 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 744 TABLE 1118 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 744 TABLE 1119 REST OF GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 745 TABLE 1120 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 745 TABLE 1121 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 746 TABLE 1122 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 746 TABLE 1123 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 747 TABLE 1124 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 747 TABLE 1125 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 747 TABLE 1126 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 748 TABLE 1127 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 748 TABLE 1128 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 748 TABLE 1129 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 749 TABLE 1130 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 749 TABLE 1131 REST OF GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 750 TABLE 1132 REST OF GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 750 TABLE 1133 REST OF GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 751 TABLE 1134 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 751 TABLE 1135 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 751 TABLE 1136 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 752 TABLE 1137 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 752 TABLE 1138 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 753 TABLE 1139 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 753 TABLE 1140 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 754 TABLE 1141 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 754 TABLE 1142 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 755 TABLE 1143 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 755 TABLE 1144 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION) 756 TABLE 1145 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 756 TABLE 1146 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION) 757 TABLE 1147 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 757 TABLE 1148 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION) 757 TABLE 1149 REST OF MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION) 758 TABLE 1150 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 758 TABLE 1151 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 759 TABLE 1152 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 759 TABLE 1153 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 760 TABLE 1154 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION) 760 TABLE 1155 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 760 TABLE 1156 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 761 TABLE 1157 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 761 TABLE 1158 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION) 761 TABLE 1159 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION) 762 TABLE 1160 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 762 TABLE 1161 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 763 TABLE 1162 REST OF MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 763 TABLE 1163 REST OF MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION) 764 TABLE 1164 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 764 TABLE 1165 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION) 764 TABLE 1166 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION) 765 TABLE 1167 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION) 765 TABLE 1168 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION) 766 TABLE 1169 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION) 766 TABLE 1170 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION) 767 TABLE 1171 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION) 767 TABLE 1172 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION) 768 TABLE 1173 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 768 TABLE 1174 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET 770 TABLE 1175 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS: DEGREE OF COMPETITION 774 TABLE 1176 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION 776 TABLE 1177 INJECTABLE DRUG DELIVERY DEVICES MARKET: REGION FOOTPRINT 783 TABLE 1178 INJECTABLE DRUG DELIVERY DEVICES MARKET: PRODUCT TYPE FOOTPRINT 783 TABLE 1179 INJECTABLE DRUG DELIVERY DEVICES MARKET: USAGE PATTERN FOOTPRINT 784 TABLE 1180 INJECTABLE DRUG DELIVERY DEVICES MARKET: THERAPEUTIC APPLICATION FOOTPRINT 785 TABLE 1181 INJECTABLE DRUG DELIVERY DEVICES MARKET: SITE OF ADMINISTRATION FOOTPRINT 786 TABLE 1182 INJECTABLE DRUG DELIVERY DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 789 TABLE 1183 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 790 TABLE 1184 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: REGION FOOTPRINT 794 TABLE 1185 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: PRODUCT TYPE FOOTPRINT 795 TABLE 1186 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: FORMULATION PACKAGING FOOTPRINT 796 TABLE 1187 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: THERAPEUTIC APPLICATION FOOTPRINT 797 TABLE 1188 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: SITE OF ADMINISTRATION TYPE FOOTPRINT 798 TABLE 1189 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 801 TABLE 1190 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 802 TABLE 1191 INJECTABLE DRUG DELIVERY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 803 TABLE 1192 INJECTABLE DRUG DELIVERY MARKET: DEALS, JANUARY 2022–MARCH 2025 804 TABLE 1193 INJECTABLE DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025 805 TABLE 1194 CARDINAL HEALTH: COMPANY OVERVIEW 806 TABLE 1195 CARDINAL HEALTH: PRODUCTS OFFERED 807 TABLE 1196 CARDINAL HEALTH: EXPANSIONS, JANUARY 2022–MARCH 2025 808 TABLE 1197 BD: COMPANY OVERVIEW 810 TABLE 1198 BD: PRODUCTS OFFERED 811 TABLE 1199 BD: DEALS, JANUARY 2022–MARCH 2025 814 TABLE 1200 BD: EXPANSIONS, JANUARY 2022–MARCH 2025 815 TABLE 1201 B. BRAUN SE: COMPANY OVERVIEW 816 TABLE 1202 B. BRAUN SE: PRODUCTS OFFERED 817 TABLE 1203 BAXTER: COMPANY OVERVIEW 820 TABLE 1204 BAXTER: PRODUCTS OFFERED 821 TABLE 1205 BAXTER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 822 TABLE 1206 TERUMO CORPORATION: COMPANY OVERVIEW 824 TABLE 1207 TERUMO CORPORATION: PRODUCTS OFFERED 825 TABLE 1208 TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 826 TABLE 1209 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2025 827 TABLE 1210 PHILLIPS-MEDSIZE CORPORATION (MOLEX): COMPANY OVERVIEW 828 TABLE 1211 PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCTS OFFERED 828 TABLE 1212 PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 829 TABLE 1213 PHILLIPS-MEDSIZE CORPORATION (MOLEX): DEALS, JANUARY 2022–MARCH 2025 829 TABLE 1214 PHILLIPS-MEDSIZE CORPORATION (MOLEX): EXPANSIONS, JANUARY 2022–MARCH 2025 829 TABLE 1215 NIPRO: COMPANY OVERVIEW 830 TABLE 1216 NIPRO: PRODUCTS OFFERED 831 TABLE 1217 NIPRO: EXPANSIONS, JANUARY 2022–MARCH 2025 832 TABLE 1218 ICU MEDICAL, INC.: COMPANY OVERVIEW 833 TABLE 1219 ICU MEDICAL, INC.: PRODUCTS OFFERED 834 TABLE 1220 ICU MEDICAL, INC.: DEALS, JANUARY 2022–MARCH 2025 835 TABLE 1221 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 836 TABLE 1222 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED 837 TABLE 1223 WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022–MARCH 2025 838 TABLE 1224 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 838 TABLE 1225 GERRESHEIMER AG: COMPANY OVERVIEW 840 TABLE 1226 GERRESHEIMER AG: PRODUCTS OFFERED 841 TABLE 1227 GERRESHEIMER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 843 TABLE 1228 GERRESHMEIMER AG: DEALS, JANUARY 2022–MARCH 2025 843 TABLE 1229 GERRESHMEIMER AG: EXPANSIONS, JANUARY 2022–MARCH 2025 844 TABLE 1230 STEVANATO: COMPANY OVERVIEW 845 TABLE 1231 STEVANATO: PRODUCTS OFFERED 846 TABLE 1232 STEVANATO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 847 TABLE 1233 STEVANATO: DEALS, JANUARY 2022–MARCH 2025 847 TABLE 1234 STEVANATO: EXPANSIONS, JANUARY 2022–MARCH 2025 848 TABLE 1235 SCHOTT PHARMA: COMPANY OVERVIEW 849 TABLE 1236 SCHOTT PHARMA: PRODUCTS OFFERED 850 TABLE 1237 SCHOTT PHARMA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 851 TABLE 1238 SCHOTT PHARMA: DEALS, JANUARY 2022–MARCH 2025 851 TABLE 1239 SCOTT PHARMA: EXPANSIONS, JANUARY 2022–MARCH 2025 852 TABLE 1240 MEDMIX: COMPANY OVERVIEW 853 TABLE 1241 MEDMIX: PRODUCTS OFFERED 854 TABLE 1242 MEDMIX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 855 TABLE 1243 MEDMIX: DEALS, JANUARY 2022–APRIL 2025 855 TABLE 1244 SOLM: COMPANY OVERVIEW 856 TABLE 1245 SOLM: PRODUCTS OFFERED 856 TABLE 1246 YPSOMED: COMPANY OVERVIEW 858 TABLE 1247 YPSOMED: PRODUCTS OFFERED 859 TABLE 1248 YPSOMED: DEALS, JANUARY 2022–MARCH 2025 860 TABLE 1249 YPSOMED: EXPANSIONS, JANUARY 2022–MARCH 2025 861 TABLE 1250 OWEN MUMFORD: COMPANY OVERVIEW 862 TABLE 1251 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW 863 TABLE 1252 POLYMEDICURE: COMPANY OVERVIEW 864 TABLE 1253 UNION MEDICO INC.: COMPANY OVERVIEW 865 TABLE 1254 SHL MEDICAL: COMPANY OVERVIEW 866 TABLE 1255 ELCAM MEDICAL: COMPANY OVERVIEW 867 TABLE 1256 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 868 TABLE 1257 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 869 TABLE 1258 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 871 TABLE 1259 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022–APRIL 2025 873 TABLE 1260 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 874 TABLE 1261 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 875 TABLE 1262 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 877 TABLE 1263 PFIZER INC.: COMPANY OVERVIEW 880 TABLE 1264 PFIZER INC.: PRODUCTS OFFERED 881 TABLE 1265 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 887 TABLE 1266 PFIZER INC.: DEALS, JANUARY 2022–APRIL 2025 888 TABLE 1267 MERCK & CO., INC.: COMPANY OVERVIEW 890 TABLE 1268 MERCK & CO., INC.: PRODUCTS OFFERED 891 TABLE 1269 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 893 TABLE 1270 MERCK & CO., INC.: DEALS, JANUARY 2022–APRIL 2025 895 TABLE 1271 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 896 TABLE 1272 NOVARTIS AG: COMPANY OVERVIEW 898 TABLE 1273 NOVARTIS AG: PRODUCTS OFFERED 899 TABLE 1274 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 900 TABLE 1275 NOVARTIS AG: DEALS, JANUARY 2022–APRIL 2025 901 TABLE 1276 NOVARTIS AG: EXPANSIONS, JANUARY 2022–APRIL 2025 902 TABLE 1277 BAYER AG: COMPANY OVERVIEW 903 TABLE 1278 BAYER AG: PRODUCTS OFFERED 904 TABLE 1279 BAYER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 905 TABLE 1280 BAYER AG: EXPANSIONS, JANUARY 2022–APRIL 2025 906 TABLE 1281 ASTRAZENECA: COMPANY OVERVIEW 907 TABLE 1282 ASTRAZENECA: PRODUCTS OFFERED 908 TABLE 1283 ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 909 TABLE 1284 ASTRAZENECA: DEALS, JANUARY 2022–APRIL 2025 914 TABLE 1285 ASTRAZENECA: EXPANSIONS, JANUARY 2022–APRIL 2025 915 TABLE 1286 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW 916 TABLE 1287 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED 917 TABLE 1288 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 919 TABLE 1289 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2022–APRIL 2025 921 TABLE 1290 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS, JANUARY 2022–APRIL 2025 922 TABLE 1291 ELI LILLY AND COMPANY: COMPANY OVERVIEW 923 TABLE 1292 ELI LILLY AND COMPANY: PRODUCTS OFFERED 924 TABLE 1293 ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 925 TABLE 1294 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–APRIL 2025 926 TABLE 1295 AMGEN INC.: COMPANY OVERVIEW 929 TABLE 1296 AMGEN INC.: PRODUCTS OFFERED 930 TABLE 1297 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 931 TABLE 1298 AMGEN INC.: DEALS, JANUARY 2022–APRIL 2025 932 TABLE 1299 AMGEN INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 932 TABLE 1300 NOVO NORDISK A/S: COMPANY OVERVIEW 934 TABLE 1301 NOVO NORDISK A/S: PRODUCTS OFFERED 935 TABLE 1302 NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 936 TABLE 1303 NOVO NORDISK A/S: DEALS, JANUARY 2022–APRIL 2025 937 TABLE 1304 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–APRIL 2025 937 TABLE 1305 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW 939 TABLE 1306 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED 940 TABLE 1307 REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 940 TABLE 1308 REGENERON PHARMACEUTICALS INC.: DEALS, JANUARY 2022–APRIL 2025 942 TABLE 1309 FRESENIUS KABI AG: COMPANY OVERVIEW 943 TABLE 1310 FRESENIUS KABI AG: PRODUCTS OFFERED 944 TABLE 1311 FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 945 TABLE 1312 UCB S.A.: COMPANY OVERVIEW 946 TABLE 1313 UCB S.A.: PRODUCTS OFFERED 947 TABLE 1314 UCB S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 948 TABLE 1315 BIO-THERA SOLUTIONS, LTD.: COMPANY OVERVIEW 949 TABLE 1316 BIO-THERA SOLUTIONS, LTD.: PRODUCTS OFFERED 950 TABLE 1317 BIO-THERA SOLUTIONS, LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 950 TABLE 1318 SAGENT: COMPANY OVERVIEW 951 TABLE 1319 VALNEVA SE: COMPANY OVERVIEW 954 TABLE 1320 XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 955 TABLE 1321 PHARMAESSENTIA CORPORATION: COMPANY OVERVIEW 956 TABLE 1322 HERON THERAPEUTICS, INC.: COMPANY OVERVIEW 957 FIGURE 1 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION 73 FIGURE 2 INJECTABLE DRUG DELIVERY MARKET REGIONAL SEGMENTATION 74 FIGURE 3 INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN 78 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 83 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 83 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 84 FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 85 FIGURE 8 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 86 FIGURE 9 TOP-DOWN APPROACH 87 FIGURE 10 BOTTOM-UP APPROACH 87 FIGURE 11 DATA TRIANGULATION METHODOLOGY 90 FIGURE 12 INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION) 93 FIGURE 13 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2025 VS. 2030 (USD BILLION) 94 FIGURE 14 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD BILLION) 94 FIGURE 15 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2025 VS. 2030 (USD BILLION) 95 FIGURE 16 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION) 96 FIGURE 17 INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 96 FIGURE 18 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT 97 FIGURE 19 RISING CHRONIC DISEASES TO DRIVE MARKET 99 FIGURE 20 DEVICES SEGMENT AND US DOMINATED NORTH AMERICAN INJECTABLE DRUG DELIVERY MARKET IN 2024 100 FIGURE 21 ASIA PACIFIC TO DOMINATE MARKET DURING FORECAST PERIOD 100 FIGURE 22 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 101 FIGURE 23 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 101 FIGURE 24 INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 102 FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 111 FIGURE 26 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PEN INJECTORS (INSULIN PENS), 2024 (USD) 113 FIGURE 27 INJECTABLE DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS 115 FIGURE 28 INJECTABLE DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS 117 FIGURE 29 INJECTABLE DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS 118 FIGURE 30 INJECTABLE DRUG DELIVERY MARKET: INVESTMENT AND FUNDING SCENARIO, 2021–2023 120 FIGURE 31 INJECTABLE DRUG DELIVERY MARKET: PATENT ANALYSIS, JANUARY 2014–MARCH 2025 124 FIGURE 32 TOP APPLICANTS FOR INJECTABLE DRUG DELIVERY PATENTS, JANUARY 2014–MARCH 2025 125 FIGURE 33 INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 136 FIGURE 34 KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS & CLINICS (INJECTABLE DRUG DELIVERY DEVICES) 138 FIGURE 35 BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES FOR TOP THREE END USERS 139 FIGURE 36 KEY BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY WITH FORMULATIONS FOR TOP THREE END USERS 139 FIGURE 37 TOTAL NUMBER OF TRIALS COMPLETED/YEAR, 2024–2032 148 FIGURE 38 AI USE CASES 151 FIGURE 39 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT, 2024 375 FIGURE 40 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT 377 FIGURE 41 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT 522 FIGURE 42 REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2022−2024 772 FIGURE 43 REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2022−2024 772 FIGURE 44 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024 773 FIGURE 45 RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024 775 FIGURE 46 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024 776 FIGURE 47 RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024 777 FIGURE 48 INJECTABLE DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON 778 FIGURE 49 R&D EXPENDITURE OF KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET, 2022−2024 778 FIGURE 50 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 779 FIGURE 51 YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 779 FIGURE 52 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 781 FIGURE 53 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT 782 FIGURE 54 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 788 FIGURE 55 INJECTABLE DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX, 2024 792 FIGURE 56 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT 793 FIGURE 57 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 800 FIGURE 58 CARDINAL HEALTH: COMPANY SNAPSHOT (2024) 807 FIGURE 59 BD: COMPANY SNAPSHOT (2024) 811 FIGURE 60 B. BRAUN SE: COMPANY SNAPSHOT (2023) 817 FIGURE 61 BAXTER: COMPANY SNAPSHOT (2024) 821 FIGURE 62 TERUMO CORPORATION: COMPANY SNAPSHOT (2023) 825 FIGURE 63 NIPRO: COMPANY SNAPSHOT (2024) 831 FIGURE 64 ICU MEDICAL, INC.: COMPANY SNAPSHOT (2024) 834 FIGURE 65 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2024) 837 FIGURE 66 GERRESHEIMER AG: COMPANY SNAPSHOT (2024) 841 FIGURE 67 STEVANATO: COMPANY SNAPSHOT (2024) 846 FIGURE 68 SCHOTT PHARMA: COMPANY SNAPSHOT (2024) 850 FIGURE 69 MEDMIX: COMPANY SNAPSHOT (2024) 854 FIGURE 70 YPSOMED: COMPANY SNAPSHOT (2024) 859 FIGURE 71 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024) 869 FIGURE 72 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 875 FIGURE 73 PFIZER INC.: COMPANY SNAPSHOT (2024) 881 FIGURE 74 MERCK & CO., INC.: COMPANY SNAPSHOT (2024) 891 FIGURE 75 NOVARTIS AG: COMPANY SNAPSHOT (2024) 899 FIGURE 76 BAYER AG: COMPANY SNAPSHOT (2024) 904 FIGURE 77 ASTRAZENECA: COMPANY SNAPSHOT (2024) 908 FIGURE 78 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2024) 917 FIGURE 79 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024) 924 FIGURE 80 AMGEN INC.: COMPANY SNAPSHOT (2024) 929 FIGURE 81 NOVO NORDISK A/S: COMPANY SNAPSHOT (2024) 935 FIGURE 82 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024) 939 FIGURE 83 FRESENIUS KABI AG: COMPANY SNAPSHOT (2024) 943 FIGURE 84 UCB S.A.: COMPANY SNAPSHOT (2024) 947 FIGURE 85 BIO-THERA SOLUTIONS, LTD.: COMPANY SNAPSHOT (2024) 949

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們